

IMMUNOMEDICS INC  
Form 8-K  
June 04, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 1, 2018**

**IMMUNOMEDICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-12104**  
(Commission File Number)

**61-1009366**  
(IRS Employer Identification No.)

**300 The American Road**  
**Morris Plains, New Jersey**  
(Address of Principal Executive Offices)

**07950**  
(Zip Code)

**(973) 605-8200**

Registrant's telephone number, including area code

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On June 3, 2018, at the 2018 ASCO Annual Meeting held in Chicago, Illinois, Immunomedics, Inc. (the Company) delivered a presentation titled Science-Based Innovation-Focused ADC Company. The presentation is attached to this current report on Form 8-K as Exhibit 99.3 and is incorporated by reference herein.

In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the presentation slides, attached to this current report on Form 8-K as Exhibit 99.3, are furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Please refer to Exhibit 99.3 for a discussion of certain forward-looking statements included therein and the risk and uncertainties related thereto.

**Item 8.01 Other Events.**

On June 1, 2018, the Company issued a press release titled Immunomedics Announces Initiation of Pivotal Study of Sacituzumab Govitecan in Patients with Locally Advanced or Metastatic Urothelial Cancer. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

On June 3, 2018, the Company issued a press release titled Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.2 and is incorporated by reference herein.

Also on June 3, 2018, the Company issued a press release titled Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.4 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibits are being filed herewith:

**Exhibit  
No.**  
99.1

**Exhibit**

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

- 99.2 [Press Release of Immunomedics, Inc., dated June 1, 2018, titled Immunomedics Announces Initiation of Pivotal Study of Sacituzumab Govitecan in Patients with Locally Advanced or Metastatic Urothelial Cancer](#)
- 99.3 [Press Release of Immunomedics, Inc., dated June 3, 2018, titled Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers](#)
- 99.4 [Immunomedics, Inc. Presentation, dated June 3, 2018](#)
- 99.4 [Press Release of Immunomedics, Inc., dated June 3, 2018, titled Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer](#)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IMMUNOMEDICS, INC.**

Date: June 4, 2018

By: /s/ Michael R. Garone  
Name: Michael R. Garone  
Title: Vice President, Finance and  
Chief Financial Officer